Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer

A fresh flop in metastatic non-small cell lung cancer (NSCLC) marks the latest in a string of clinical losses for the pairing of Exelixis and Ipsen's tyrosine kinase inhibitor Cabometyx and Roche’s immuno-oncology star Tecentriq.